RxDoctor Payments Data

William Rogers

Family · Canfield, OHNPI 1407203714

Payments from drug & device makers

$2,052in general payments, 2019–2025

Across 91 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$595
  • Takeda Pharmaceuticals U.S.A., Inc.$346
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$208
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$194
  • Ironwood Pharmaceuticals, Inc$160
  • Intercept Pharmaceuticals, Inc.$112
  • plus $437 from 10 others

What the payments were for

  • Food & beverage$2,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,052 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$10,978
Medicare patients
126
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide73$50,988
CreonLipase/Protease/Amylase11$26,477
Dexlansoprazole DrDexlansoprazole17$3,454
Pantoprazole Sodium202$2,352
Famotidine161$1,692
Colestipol Hcl34$1,677
Omeprazole94$1,424
Esomeprazole Magnesium16$1,089
Sucralfate16$300
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl12$176
Dicyclomine Hcl13$110
Metronidazole17$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$595$77,46584 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Canfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →